Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China.
Adv Exp Med Biol. 2021;1318:435-448. doi: 10.1007/978-3-030-63761-3_25.
Since the outbreak of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2, the disease has spread rapidly worldwide and developed into a global pandemic, causing a significant impact on the global health system and economic development. Scientists have been racing to find effective drugs and vaccines for the treatment and prevention of COVID-19. However, due to the diversity of clinical manifestations caused by COVID-19, no standard antiviral regimen beyond supportive therapy has been established. Ongoing clinical trials are underway to evaluate the efficacy of drugs that primarily act on the viral replication cycle or enhanced immunity of patients. This chapter will summarize the currently used antiviral and adjuvant therapies in clinical practice and provide a theoretical basis for the future treatment of COVID-19.
自 2019 年冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起以来，该疾病在全球迅速传播并发展成为全球大流行，对全球卫生系统和经济发展造成重大影响。科学家们一直在竞相寻找 COVID-19 的治疗和预防的有效药物和疫苗。然而，由于 COVID-19 引起的临床表现多样化，除了支持性治疗之外，尚未建立标准的抗病毒方案。正在进行的临床试验正在评估主要作用于病毒复制周期或增强患者免疫力的药物的疗效。本章将总结目前在临床实践中使用的抗病毒和辅助治疗方法，并为 COVID-19 的未来治疗提供理论依据。
